U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109817) titled 'Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer' on July 31.
Brief Summary: This is a double-blinded randomized controlled clinical trial that aims to study if desloratadine can reduce rates of peripheral neuropathy development in patients with breast cancer receiving taxane chemotherapy. Researchers will compare desloratadine to a placebo (look-alike substance with no drug) and use validated neurotoxicity and quality of life questionnaires to determine if desloratadine can be used to prevent or make taxane induced peripheral neuropathy (TPIN) symptoms better.
Study Start Date: Aug., 2025...